Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01365104 · ClinicalTrials.gov registry record · Early Phase 1
Modulation of Cerebral Blood Flow Using Iron Chelators
A Early Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 97
- Enrollment target
NCT01365104 is a Early Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 97 participants.
The verdict
NCT01365104, a Early Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.
Interventions
- DRUG desferrioxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01365104
The ClinicalTrials.gov registry entry for NCT01365104 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which desferrioxamine is the first listed.
NCT01365104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01365104 about?
NCT01365104 is a clinical study titled "Modulation of Cerebral Blood Flow Using Iron Chelators". The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.
What is the current status of trial NCT01365104?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 97 participants. The study started on 2008-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01365104?
The interventions under investigation include: desferrioxamine (DRUG).
Who is sponsoring clinical trial NCT01365104?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.